

VU Research Portal

89Zr-immuno-PET

Jauw, Y.W.S.

2019

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Jauw, Y. W. S. (2019). *89Zr-immuno-PET: Towards a clinical tool to guide antibody-based therapy in cancer*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

| | | |
|----------------|---|-----------|
| Chapter 1 | General introduction | 9 |
| Part I | Feasibility of ^{89}Zr-immuno-PET | 19 |
| Chapter 2 | Radiation dosimetry of ^{89}Zr -labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. <i>J Nucl Med.</i> 2009;50:1828-36 | 21 |
| Chapter 3 | Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. <i>Clin Can Res.</i> 2006;12:2133-40 | 43 |
| Chapter 4 | Immuno-positron emission tomography with Zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? <i>Front Pharmacol.</i> 2016;24;7:131 | 63 |
| Part II | Validation of ^{89}Zr-immuno-PET | 95 |
| Chapter 5 | Noise-induced variability of immuno-PET with Zirconium-89-labeled antibodies: an analysis based on count-reduced clinical images. <i>Mol Imaging Biol.</i> 2018;20:1025-1034 | 97 |
| Chapter 6 | Interobserver reproducibility of tumor uptake quantification with ^{89}Zr -immuno-PET: a multicenter analysis. <i>Eur J Nucl Med Mol Imaging.</i> 2019; 2019;46:1840-1849 | 121 |

| | | |
|------------|---|-----|
| Chapter 7 | Performance of ^{89}Zr -labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. <i>PLoS ONE</i> . 2017;12:e0169828. | 141 |
| Chapter 8 | Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Res</i> . 2018; 8:6. | 157 |
| Chapter 9 | ^{89}Zr -immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo. <i>J Nucl Med</i> . 2019; Epub ahead of print | 175 |
| Chapter 10 | Summary and discussion | 195 |
| Addendum | | 211 |
| | Nederlandse samenvatting | 213 |
| | Acknowledgements / Dankwoord | 222 |
| | Curriculum vitae | 224 |
| | List of publications | 225 |
| | List of abbreviations | 230 |